Viewing nowCombinationVR Tablet 10/80 mg
Rosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 202003039 · Approved 2020.04.24 · Insurance code 645906940
Treatment of hypertension and heart failure; improvement of dyslipidemia; inhibition of atherosclerosis and cardiovascular and mortality risk
This medication is used for patients who need to take both valsartan and rosuvastatin simultaneously. Valsartan is used to treat essential hypertension, heart failure, particularly in heart failure patients intolerant to ACE inhibitors, and to reduce the risk of death after myocardial infarction. Rosuvastatin helps in cholesterol control in patients with hypercholesterolemia and mixed hyperlipidemia, delays the progression of atherosclerosis, and reduces the risk of cardiovascular disease. It is particularly effective in reducing the risk of stroke, myocardial infarction, and revascularization in patients with high sensitive C-reactive protein levels. Therefore, this medication improves the management of hypertension and hyperlipidemia, and reduces the risk of cardiovascular disease.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is administered concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following weeks, the dose may be increased according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Essential hypertension: Safety and efficacy have not been established in children and adolescents under 18 years of age. Heart failure: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause severe harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. It is advisable for pregnant or nursing women, as well as women of childbearing potential, not to use this medication. If necessary, adequate counseling and proper contraception are required. Patients with severe liver impairment or certain kidney diseases and muscle disorders should not use this medication, and caution is needed in patients with mild liver or kidney dysfunction. Elderly patients, patients with high serum potassium levels, or those at risk of rapid blood pressure drop should also exercise caution when taking this medication. This medication can cause side effects such as myalgia, muscle weakness, and rarely severe muscle damage, so patients should consult a doctor immediately if they experience muscle-related symptoms. Regular checks may be needed due to possible changes in liver function or blood test results. This medication may interact with other drugs, so patients should inform their physician, especially when taking potassium-sparing diuretics, certain antibiotics, or other lipid-lowering medications. Dizziness or blood pressure drops may occur during treatment, so caution is advised when driving or operating machinery. Pregnant women must have appropriate contraception as this medication can inhibit cholesterol synthesis imperative for fetal development, and it must be discontinued immediately upon confirmation of pregnancy. Safety and efficacy have not been established in children and adolescents, so it is best not to use this medication in this age group. In cases of overdose, patients should visit a medical institution immediately for proper treatment, as blood dialysis may be ineffective. Ensure that it is stored out of children's reach and that the container is not changed.
Indigestion, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusions, elevated serum liver aminotransferases (AST, ALT), increased serum creatine phosphokinase, elevated serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory disturbance, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fractures, spinal fractures, fractures, skin neoplasms, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, herniated disc, hemoptysis, sputum disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, elevated triglycerides, increased blood pressure, exacerbation of hypertension, neck/shoulder pain, toe fractures, osteomyelitis, skin infections, unspecified dermatitis, localized skin reactions, palpitations, exacerbation of angina, auditory disturbances, overactive bladder, increased serum creatinine, reproductive dysfunction (male), benign prostatic hyperplasia, lacerations, headache, dizziness, viral infections, upper respiratory tract infections, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain (low back pain), abdominal pain, pharyngitis, arthralgia, hypotension, postural dizziness, orthostatic hypotension, renal impairment, hyperkalemia, drowsiness, atrial fibrillation, loss of appetite, lethargy, vascular edema, erythema, pruritus, serum sickness, vasculitis, hepatitis, arrhythmia, intestinal vascular edema, interstitial pneumonia, hypoglycemia, shock, syncope, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, reduced hematocrit, decreased hemoglobin, edema, constipation, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, weakness, polyneuropathy, memory loss, peripheral neuropathy, respiratory distress, jaundice, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome (DRESS), lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light, so it must be stored in a container that does not allow light to penetrate. Additionally, it is recommended to store the medication at room temperature, avoiding extremes of heat or cold, ideally between 1 degree and 30 degrees Celsius.
Pink round film-coated tablet
30 tablets/box [(10 tablets/PTP) * 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Medika Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.